Since the discovery of hybridoma technology by Caesar Milstein and Georges Köhler in 1975, monoclonal antibodies (mAbs) have become one of the most relevant methodological advances in biomedicine.
MAbs have provided researchers with the ability to study biological processes reliably and with unprecedented accuracy, improving our knowledge about the processes involved in tumour generation and development. Beyond their applications in the laboratory as research tools, mAbs are also used in the area of diagnostics, and serve as therapeutic agents in the treatment of cancer.
The Monoclonal Antibodies Unit provides CNIO Research Groups with à la carte generation of mAbs using hybridoma technology. We are highly specialised in the production of mouse and rat monoclonal antibodies. The Unit also offers mAb characterisation and validation, medium-scale mAb production, as well as a Mycoplasma testing service for the cell culture facility.